Combination testing may identify who benefits from dose optimization in Crohn’s

Among patients with Crohn’s disease, combination testing of the endoscopic healing index and anti-tumor necrosis factor concentration may identify patients who benefit from dose escalation, according to data from Digestive Disease Week.“This is a hypothesis generating study using mined data from a large commercial clinical laboratory database,” Maria T. Abreu, MD, from the University of Miami Miller School of Medicine, said during her virtual presentation. “We propose combined measurement of endoscopic healing index [EHI] scores with anti-TNF concentrations couldRead More

Share on facebook
Share on twitter
Share on linkedin